This effect paralleled the induction of the well-known PPAR target PDK4. These data suggest that PPARα activation by pemafibrate in LSECs is pivotal for the prevention of NASH in STAM mouse livers. Here, PDK4 is linked to metabolic dysfunction-associated steatohepatitis.